Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 10/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125589 | 0.89 | MTNR1A (0.63) | MTNR1AMTNR1BLMNAMAPTTP53 | |
| SCHEMBL172491 | 0.87 | MTNR1A (0.52) | MTNR1AMTNR1BLMNAKMT2AALDH1A1 | |
| SCHEMBL13498607 | 0.80 | MTNR1A (0.62) | MTNR1AMTNR1BMAPTTP53ALDH1A1 | |
| SCHEMBL126984 | 0.78 | MTNR1B (0.82) | MTNR1AMTNR1B | |
| SCHEMBL124654 | 0.78 | MTNR1A (0.53) | MTNR1AMTNR1BMAPT | |
| SCHEMBL124170 | 0.78 | MTNR1A (0.65) | MTNR1AMTNR1B | |
| SCHEMBL172381 | 0.77 | MTNR1B (0.62) | MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL126117 | 0.77 | MTNR1B (0.71) | MTNR1AMTNR1B | |
| SCHEMBL5395592 | 0.74 | MAPK14 (0.55) | LMNAMAPTTP53MEN1KMT2A | |
| SCHEMBL172421 | 0.74 | MTNR1A (0.54) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273761-B2 | Tricyclic compound and medical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273761-B2 | Tricyclic compound and medical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2100895-B1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2100895-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029707-A1 | TRICYCLIC COMPOUND AND MEDICAL USE THEREOF | MTNR1A, MTNR1B, AHR | MTNR1A 1/4885MTNR1B 2/4885LMNA 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.